Barclays
TVRD

Barclays’s Tvardi Therapeutics TVRD Stock Holding History

Barclays’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.01K Sell
946
-7,361
-89% -$28.8K ﹤0.01% 4819
2025
Q4 		$35.7K Buy
8,307
+1,638
+25% +$14.7K ﹤0.01% 4790
2025
Q3 		$260K Buy
6,669
+880
+15% +$25.1K ﹤0.01% 4176
2025
Q2 		$135K Buy
+5,789
New +$137K ﹤0.01% 4495
2024
Q3 		– Sell
-459
Closed -$4.26K – 5534
2024
Q2 		$4.26K Sell
459
-442
-49% -$10.5K ﹤0.01% 4589
2024
Q1 		$29.5K Sell
901
-877
-49% -$22.7K ﹤0.01% 4705
2023
Q4 		$47.6K Buy
1,778
+1,561
+719% +$64.6K ﹤0.01% 4780
2023
Q3 		$13.2K Sell
217
-43
-17% -$4.03K ﹤0.01% 4261
2023
Q2 		$26.4K Sell
260
-530
-67% -$73K ﹤0.01% 4078
2023
Q1 		$140K Sell
790
-28
-3% -$9.38K ﹤0.01% 3991
2022
Q4 		$316K Buy
818
+326
+66% +$124K ﹤0.01% 3591
2022
Q3 		$166K Sell
492
-487
-50% -$176K ﹤0.01% 3308
2022
Q2 		$322K Sell
979
-155
-14% -$54.4K ﹤0.01% 3152
2022
Q1 		$496K Sell
1,134
-1,107
-49% -$454K ﹤0.01% 2914
2021
Q4 		$983K Buy
2,241
+833
+59% +$419K ﹤0.01% 2845
2021
Q3 		$782K Buy
1,408
+644
+84% +$323K ﹤0.01% 2925
2021
Q2 		$393K Sell
764
-345
-31% -$219K ﹤0.01% 3206
2021
Q1 		$867K Buy
1,109
+648
+141% +$444K ﹤0.01% 2863
2020
Q4 		$251K Sell
461
-153
-25% -$80.2K ﹤0.01% 3638
2020
Q3 		$282K Sell
614
-257
-30% -$149K ﹤0.01% 3623
2020
Q2 		$536K Buy
871
+418
+92% +$231K ﹤0.01% 3292
2020
Q1 		$216K Sell
453
-1,469
-76% -$798K ﹤0.01% 4241
2019
Q4 		$1.11M Buy
1,922
+296
+18% +$208K ﹤0.01% 3575
2019
Q3 		$1.07M Buy
1,626
+777
+92% +$646K ﹤0.01% 3603
2019
Q2 		$657K Sell
849
-931
-52% -$654K ﹤0.01% 4091
2019
Q1 		$1.26M Sell
1,780
-273
-13% -$163K ﹤0.01% 3147
2018
Q4 		$961K Buy
2,053
+1,239
+152% +$799K ﹤0.01% 3149
2018
Q3 		$701K Sell
814
-1,656
-67% -$1.2M ﹤0.01% 3982
2018
Q2 		$1.7M Buy
2,470
+2,245
+998% +$1.14M ﹤0.01% 2722
2018
Q1 		$99K Sell
225
-329
-59% -$160K ﹤0.01% 5391
2017
Q4 		$244K Sell
554
-1,827
-77% -$833K ﹤0.01% 4521
2017
Q3 		$1.17M Sell
2,381
-299
-11% -$150K ﹤0.01% 2851
2017
Q2 		$1.49M Buy
2,680
+616
+30% +$391K ﹤0.01% 2520
2017
Q1 		$1.37M Buy
2,064
+210
+11% +$112K ﹤0.01% 2446
2016
Q4 		$620K Buy
1,854
+1,850
+46,250% +$594K ﹤0.01% 3177
2016
Q3 		$1K Sell
4
-8
-67% -$1.73K ﹤0.01% 6466
2016
Q2 		$2K Buy
12
+5
+71% +$1.09K ﹤0.01% 6002
2016
Q1 		$2K Sell
7
-52
-88% -$15.5K ﹤0.01% 5899
2015
Q4 		$35K Sell
59
-206
-78% -$113K ﹤0.01% 4977
2015
Q3 		$133K Buy
265
+254
+2,309% +$170K ﹤0.01% 4430
2015
Q2 		$5K Sell
11
-2
-15% -$773 ﹤0.01% 6475
2015
Q1 		$5K Buy
13
+2
+18% +$757 ﹤0.01% 6605
2014
Q4 		$4K Buy
11
+6
+120% +$1.93K ﹤0.01% 7026
2014
Q3 		$1K Buy
5
+3
+150% +$1.23K ﹤0.01% 7543
2014
Q2 		$1K Sell
2
-2
-50% -$1.08K ﹤0.01% 7533
2014
Q1 		$3K Buy
+4
New +$2.37K ﹤0.01% 7344

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $361M AUM 18% 1-Year Est. Return

Barclays's TVRD Position: Q1 2026 in Review

Barclays reduced its Tvardi Therapeutics (TVRD) stake by 89% in Q1 2026, selling an estimated $28.8K and leaving 946 shares worth $3.01K. The position accounts for ﹤0.01% of the portfolio, ranked #4819.

Barclays first reported a position in TVRD in Q1 2014 and has held it in 46 quarters since. The position peaked at $1.7M in Q2 2018. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • Barclays held 946 shares of Tvardi Therapeutics worth $3.01K as of Q1 2026.
  • Barclays sold 7,361 Tvardi Therapeutics shares in Q1 2026, an estimated $28.8K.
  • Tvardi Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4819 holding.
  • Barclays first reported a position in Tvardi Therapeutics in Q1 2014 and has held it in 46 quarters since.
  • Barclays's Tvardi Therapeutics position peaked at $1.7M in Q2 2018.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.